Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4- R)

Tatsuro Katsuno, Tapas K. Pradhan, Richard R. Ryan, Samuel A. Mantey, Wei Hou, Patrick J. Donohue, Mark A. Akeson, Eliot Spindel, James F. Battey, David H. Coy, Robert T. Jensen

    Research output: Contribution to journalArticle

    43 Citations (Scopus)

    Abstract

    Recently, a fourth member of the bombesin (Bn) receptor family (fBB4- R) was isolated from a cDNA library from the brain of the frog, Bombina orientalis. Its pharmacology and cell biology are largely unknown, and no known natural cell lines or tissues possess sufficient numbers of fBB4-R's to allow either of these to be determined. To address these issues, we have used three different strategies. fBB4-R expression in cells widely used for other Bn receptor subtypes was unsuccessful as was expression in two frog cell lines. However, stable fBB4-R cell lines were obtained in CHO-K1 cells which were shown to faithfully demonstrate the correct pharmacology of the related Bn receptor, the GRP receptor, when expressed in these cells. [DPhe6,βAla11,Phe13,Nle14]Bn(6-14) was found to have high affinity (K(i) = 0.4 nM) for the fBB4 receptor and 125I- [DTyr6,βala11,Phe13,Nle14]Bn(6-14) to be an excellent ligand for this receptor. The fBB4-R had a unique pharmacology for naturally occurring Bn- related agonists, with the presence of a penultimate phenylalanine being critical for high-affinity interaction. It also had a unique profile for six classes of Bn antagonists. The fBB4-R was coupled to phospholipase C with activation increasing [3H]inositol phosphates and mobilizing Ca2+ almost entirely from cellular sources. There was a close correlation between agonist the receptor occupation and the receptor activation. Three of the five classes of Bn receptor antagonists that interacted with higher affinity with the fBB4-R functioned as fBB4-R antagonists and two as partial agonists, fBB4-R activation stimulated increases in phospholipase D (PLD) over the same range of concentrations at which it activated phospholipase C. These results demonstrate that the fBB4 receptor has a unique pharmacology for agonists and antagonists and is coupled to phospholipase C and D. The availability of these cell lines, this novel ligand, and the identification of three classes of antagonists that can be used as lead compounds should facilitate the further investigation of the pharmacology and cell biology of the BB4 receptor.

    Original languageEnglish (US)
    Pages (from-to)7307-7320
    Number of pages14
    JournalBiochemistry
    Volume38
    Issue number22
    DOIs
    StatePublished - Jun 1 1999

    Fingerprint

    Bombesin Receptors
    Cytology
    Bombesin
    Cell Biology
    Type C Phospholipases
    Cells
    Pharmacology
    Phospholipase D
    Anura
    Chemical activation
    Cell Line
    Ligands
    Lead compounds
    Inositol Phosphates
    Phenylalanine
    Gene Library
    CHO Cells
    Brain
    Availability
    Tissue

    ASJC Scopus subject areas

    • Biochemistry

    Cite this

    Katsuno, T., Pradhan, T. K., Ryan, R. R., Mantey, S. A., Hou, W., Donohue, P. J., ... Jensen, R. T. (1999). Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4- R). Biochemistry, 38(22), 7307-7320. https://doi.org/10.1021/bi990204w

    Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4- R). / Katsuno, Tatsuro; Pradhan, Tapas K.; Ryan, Richard R.; Mantey, Samuel A.; Hou, Wei; Donohue, Patrick J.; Akeson, Mark A.; Spindel, Eliot; Battey, James F.; Coy, David H.; Jensen, Robert T.

    In: Biochemistry, Vol. 38, No. 22, 01.06.1999, p. 7307-7320.

    Research output: Contribution to journalArticle

    Katsuno, T, Pradhan, TK, Ryan, RR, Mantey, SA, Hou, W, Donohue, PJ, Akeson, MA, Spindel, E, Battey, JF, Coy, DH & Jensen, RT 1999, 'Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4- R)', Biochemistry, vol. 38, no. 22, pp. 7307-7320. https://doi.org/10.1021/bi990204w
    Katsuno T, Pradhan TK, Ryan RR, Mantey SA, Hou W, Donohue PJ et al. Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4- R). Biochemistry. 1999 Jun 1;38(22):7307-7320. https://doi.org/10.1021/bi990204w
    Katsuno, Tatsuro ; Pradhan, Tapas K. ; Ryan, Richard R. ; Mantey, Samuel A. ; Hou, Wei ; Donohue, Patrick J. ; Akeson, Mark A. ; Spindel, Eliot ; Battey, James F. ; Coy, David H. ; Jensen, Robert T. / Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4- R). In: Biochemistry. 1999 ; Vol. 38, No. 22. pp. 7307-7320.
    @article{7ea66a30ab304196974e2595473c61b1,
    title = "Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4- R)",
    abstract = "Recently, a fourth member of the bombesin (Bn) receptor family (fBB4- R) was isolated from a cDNA library from the brain of the frog, Bombina orientalis. Its pharmacology and cell biology are largely unknown, and no known natural cell lines or tissues possess sufficient numbers of fBB4-R's to allow either of these to be determined. To address these issues, we have used three different strategies. fBB4-R expression in cells widely used for other Bn receptor subtypes was unsuccessful as was expression in two frog cell lines. However, stable fBB4-R cell lines were obtained in CHO-K1 cells which were shown to faithfully demonstrate the correct pharmacology of the related Bn receptor, the GRP receptor, when expressed in these cells. [DPhe6,βAla11,Phe13,Nle14]Bn(6-14) was found to have high affinity (K(i) = 0.4 nM) for the fBB4 receptor and 125I- [DTyr6,βala11,Phe13,Nle14]Bn(6-14) to be an excellent ligand for this receptor. The fBB4-R had a unique pharmacology for naturally occurring Bn- related agonists, with the presence of a penultimate phenylalanine being critical for high-affinity interaction. It also had a unique profile for six classes of Bn antagonists. The fBB4-R was coupled to phospholipase C with activation increasing [3H]inositol phosphates and mobilizing Ca2+ almost entirely from cellular sources. There was a close correlation between agonist the receptor occupation and the receptor activation. Three of the five classes of Bn receptor antagonists that interacted with higher affinity with the fBB4-R functioned as fBB4-R antagonists and two as partial agonists, fBB4-R activation stimulated increases in phospholipase D (PLD) over the same range of concentrations at which it activated phospholipase C. These results demonstrate that the fBB4 receptor has a unique pharmacology for agonists and antagonists and is coupled to phospholipase C and D. The availability of these cell lines, this novel ligand, and the identification of three classes of antagonists that can be used as lead compounds should facilitate the further investigation of the pharmacology and cell biology of the BB4 receptor.",
    author = "Tatsuro Katsuno and Pradhan, {Tapas K.} and Ryan, {Richard R.} and Mantey, {Samuel A.} and Wei Hou and Donohue, {Patrick J.} and Akeson, {Mark A.} and Eliot Spindel and Battey, {James F.} and Coy, {David H.} and Jensen, {Robert T.}",
    year = "1999",
    month = "6",
    day = "1",
    doi = "10.1021/bi990204w",
    language = "English (US)",
    volume = "38",
    pages = "7307--7320",
    journal = "Biochemistry",
    issn = "0006-2960",
    publisher = "American Chemical Society",
    number = "22",

    }

    TY - JOUR

    T1 - Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4- R)

    AU - Katsuno, Tatsuro

    AU - Pradhan, Tapas K.

    AU - Ryan, Richard R.

    AU - Mantey, Samuel A.

    AU - Hou, Wei

    AU - Donohue, Patrick J.

    AU - Akeson, Mark A.

    AU - Spindel, Eliot

    AU - Battey, James F.

    AU - Coy, David H.

    AU - Jensen, Robert T.

    PY - 1999/6/1

    Y1 - 1999/6/1

    N2 - Recently, a fourth member of the bombesin (Bn) receptor family (fBB4- R) was isolated from a cDNA library from the brain of the frog, Bombina orientalis. Its pharmacology and cell biology are largely unknown, and no known natural cell lines or tissues possess sufficient numbers of fBB4-R's to allow either of these to be determined. To address these issues, we have used three different strategies. fBB4-R expression in cells widely used for other Bn receptor subtypes was unsuccessful as was expression in two frog cell lines. However, stable fBB4-R cell lines were obtained in CHO-K1 cells which were shown to faithfully demonstrate the correct pharmacology of the related Bn receptor, the GRP receptor, when expressed in these cells. [DPhe6,βAla11,Phe13,Nle14]Bn(6-14) was found to have high affinity (K(i) = 0.4 nM) for the fBB4 receptor and 125I- [DTyr6,βala11,Phe13,Nle14]Bn(6-14) to be an excellent ligand for this receptor. The fBB4-R had a unique pharmacology for naturally occurring Bn- related agonists, with the presence of a penultimate phenylalanine being critical for high-affinity interaction. It also had a unique profile for six classes of Bn antagonists. The fBB4-R was coupled to phospholipase C with activation increasing [3H]inositol phosphates and mobilizing Ca2+ almost entirely from cellular sources. There was a close correlation between agonist the receptor occupation and the receptor activation. Three of the five classes of Bn receptor antagonists that interacted with higher affinity with the fBB4-R functioned as fBB4-R antagonists and two as partial agonists, fBB4-R activation stimulated increases in phospholipase D (PLD) over the same range of concentrations at which it activated phospholipase C. These results demonstrate that the fBB4 receptor has a unique pharmacology for agonists and antagonists and is coupled to phospholipase C and D. The availability of these cell lines, this novel ligand, and the identification of three classes of antagonists that can be used as lead compounds should facilitate the further investigation of the pharmacology and cell biology of the BB4 receptor.

    AB - Recently, a fourth member of the bombesin (Bn) receptor family (fBB4- R) was isolated from a cDNA library from the brain of the frog, Bombina orientalis. Its pharmacology and cell biology are largely unknown, and no known natural cell lines or tissues possess sufficient numbers of fBB4-R's to allow either of these to be determined. To address these issues, we have used three different strategies. fBB4-R expression in cells widely used for other Bn receptor subtypes was unsuccessful as was expression in two frog cell lines. However, stable fBB4-R cell lines were obtained in CHO-K1 cells which were shown to faithfully demonstrate the correct pharmacology of the related Bn receptor, the GRP receptor, when expressed in these cells. [DPhe6,βAla11,Phe13,Nle14]Bn(6-14) was found to have high affinity (K(i) = 0.4 nM) for the fBB4 receptor and 125I- [DTyr6,βala11,Phe13,Nle14]Bn(6-14) to be an excellent ligand for this receptor. The fBB4-R had a unique pharmacology for naturally occurring Bn- related agonists, with the presence of a penultimate phenylalanine being critical for high-affinity interaction. It also had a unique profile for six classes of Bn antagonists. The fBB4-R was coupled to phospholipase C with activation increasing [3H]inositol phosphates and mobilizing Ca2+ almost entirely from cellular sources. There was a close correlation between agonist the receptor occupation and the receptor activation. Three of the five classes of Bn receptor antagonists that interacted with higher affinity with the fBB4-R functioned as fBB4-R antagonists and two as partial agonists, fBB4-R activation stimulated increases in phospholipase D (PLD) over the same range of concentrations at which it activated phospholipase C. These results demonstrate that the fBB4 receptor has a unique pharmacology for agonists and antagonists and is coupled to phospholipase C and D. The availability of these cell lines, this novel ligand, and the identification of three classes of antagonists that can be used as lead compounds should facilitate the further investigation of the pharmacology and cell biology of the BB4 receptor.

    UR - http://www.scopus.com/inward/record.url?scp=0033153359&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0033153359&partnerID=8YFLogxK

    U2 - 10.1021/bi990204w

    DO - 10.1021/bi990204w

    M3 - Article

    VL - 38

    SP - 7307

    EP - 7320

    JO - Biochemistry

    JF - Biochemistry

    SN - 0006-2960

    IS - 22

    ER -